[Therapy of acute pancreatitis with a synthetic protease and phospholipase A2 inhibitor gabexate mesilate].
In order to evaluate the efficacy and safety of gabexate mesilate (FOY = [ethyl-4-(6-guanidinohexanoyloxy) benzoate methane sulfonate]), a synthetic inhibitor of various proteases as well as phospholipase A 2, 17 patients with acute pancreatitis were treated with FOY in doses of 3 X 150 mg/day per i.v. perfusor. The clinical course of the disease and the laboratory findings were compared with the results of a control group of 21 patients also suffering from acute pancreatitis. 30% of the patients in the FOY-group and 40% in the control group had different complications during the first week after admission to the hospital. The laboratory findings in the two groups revealed that alpha-amylase levels in serum and urine in the FOY-group were significantly lower than in the control group. Side effects of the drug were not observed. FOY may be considered a promising drug for treatment of acute pancreatitis in view of its few side effects and especially with regard to its mode of action.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000681:Amylases / Q000097:blood; D005260:Female; D016670:Gabexate; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000188:drug therapy* / Q000201:enzymology; D010740:Phospholipases / Q000627:therapeutic use*; D010741:Phospholipases A / Q000627:therapeutic use*; D054467:Phospholipases A2; D011480:Protease Inhibitors / Q000627:therapeutic use*
D006146:Guanidines; D011480:Protease Inhibitors; D016670:Gabexate; D010740:Phospholipases; D010741:Phospholipases A; D054467:Phospholipases A2; D000681:Amylases
Therapie der akuten Pankreatitis mit dem synthetischen Proteasen- und Phospholipase A2-Inhibitor Gabexat mesilat.